1. Home
  2. CRGX vs HBT Comparison

CRGX vs HBT Comparison

Compare CRGX & HBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRGX
  • HBT
  • Stock Information
  • Founded
  • CRGX 2021
  • HBT 1920
  • Country
  • CRGX United States
  • HBT United States
  • Employees
  • CRGX N/A
  • HBT N/A
  • Industry
  • CRGX
  • HBT Major Banks
  • Sector
  • CRGX
  • HBT Finance
  • Exchange
  • CRGX Nasdaq
  • HBT Nasdaq
  • Market Cap
  • CRGX 815.7M
  • HBT 743.2M
  • IPO Year
  • CRGX 2023
  • HBT 2019
  • Fundamental
  • Price
  • CRGX $21.70
  • HBT $23.10
  • Analyst Decision
  • CRGX Strong Buy
  • HBT Hold
  • Analyst Count
  • CRGX 7
  • HBT 6
  • Target Price
  • CRGX $30.33
  • HBT $24.00
  • AVG Volume (30 Days)
  • CRGX 416.1K
  • HBT 31.2K
  • Earning Date
  • CRGX 11-21-2024
  • HBT 10-21-2024
  • Dividend Yield
  • CRGX N/A
  • HBT 3.33%
  • EPS Growth
  • CRGX N/A
  • HBT 19.58
  • EPS
  • CRGX N/A
  • HBT 2.24
  • Revenue
  • CRGX N/A
  • HBT $213,790,000.00
  • Revenue This Year
  • CRGX N/A
  • HBT N/A
  • Revenue Next Year
  • CRGX N/A
  • HBT $0.23
  • P/E Ratio
  • CRGX N/A
  • HBT $10.21
  • Revenue Growth
  • CRGX N/A
  • HBT 2.31
  • 52 Week Low
  • CRGX $13.14
  • HBT $17.69
  • 52 Week High
  • CRGX $33.92
  • HBT $24.85
  • Technical
  • Relative Strength Index (RSI)
  • CRGX 58.91
  • HBT 64.40
  • Support Level
  • CRGX $19.61
  • HBT $20.77
  • Resistance Level
  • CRGX $19.51
  • HBT $22.18
  • Average True Range (ATR)
  • CRGX 1.19
  • HBT 0.41
  • MACD
  • CRGX 0.36
  • HBT 0.19
  • Stochastic Oscillator
  • CRGX 73.67
  • HBT 98.39

About CRGX CARGO Therapeutics Inc.

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.

About HBT HBT Financial Inc.

HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking.

Share on Social Networks: